Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase IB study of PKC412, an oral FLT3 kinase inhibito in sequential and simultaneous combination with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML

Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian H, DeAngelo DJ, Yu R, Xhang L, Cohen PS, Wang Y, Phillips P, Giles F. Phase IB study of PKC412, an oral FLT3 kinase inhibito in sequential and simultaneous combination with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML. Blood. 2005; 106:121a.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.